Authorization

Oxurion NV Reports Positive Topline Data from Phase 1 study evaluating THR-687 for treatment of DME

Oxurion NV Reports Positive Topline Data from Phase 1 study evaluating THR-687 for treatment of DME
A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A  A A A A A A A A A A A A A A A A A A A A  A THR-687 is a potent pan-RGD integrin antagonist in development for DME and DR
A A A A A A A 

Topline data show that THR-687 is well-tolerated and safe. No dose-limiting toxicities or serious adverse events reported



Rapid onset of action and prolonged effect on Best Corrected Visual Acuity (BCVA) seen across all doses of THR-687 following a single injection A 

Mean BCVA improvement of 3.1 letters at Day 1



Mean BCVA improvement of 9.2 letters at Month 1



Mean BCVA improvement of 8.3 letters at Month 3





A dose response effect in BCVA and Central Subfield Thickness (CST) was shown



Phase 2 study planned for H2 2020 with this VEGF-independent treatment option in the treatment of naA?ve DME patients

A A A A A A A 
Leuven, Belgium, 7 January 2020 a?? 07.00 AM CET a?? Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing a pipeline of novel clinical drug candidates acting on VEGF-independent pathways to preserve vision in patients with diabetic eye disease, today reports positive topline data from a Phase 1 study with THR-687, a novel, potent, pan-RGD integrin antagonist for the treatment of Diabetic Macular Edema (DME).The Phase 1, open-label, multi-center (US), single dose escalation study evaluated the safety of a single intravitreal injection ofA 3 increasing doses (0.4 mg, 1.0 mg, 2.5 mg) of THR-687 for the treatment of DME (NCT03666923). Patients recruited into the study had a history of response to prior anti-VEGF and/or corticosteroid treatment. At baseline, the study patient population had a mean BCVA of 56 letters, and a mean Central Subfield Thickness (CST) of 542Aµm.Topline data from the trial show that THR-687 is well-tolerated and safe with no dose-limiting toxicities. No serious adverse events were reported at any of the doses evaluated in the study.
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Январь 2020    »
ПнВтСрЧтПтСбВс
 12345
6789101112
13141516171819
20212223242526
2728293031